JP2007517037A5 - - Google Patents

Download PDF

Info

Publication number
JP2007517037A5
JP2007517037A5 JP2006547316A JP2006547316A JP2007517037A5 JP 2007517037 A5 JP2007517037 A5 JP 2007517037A5 JP 2006547316 A JP2006547316 A JP 2006547316A JP 2006547316 A JP2006547316 A JP 2006547316A JP 2007517037 A5 JP2007517037 A5 JP 2007517037A5
Authority
JP
Japan
Prior art keywords
carbons
alkyl
carbon atoms
group
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006547316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517037A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/043148 external-priority patent/WO2005066116A1/en
Publication of JP2007517037A publication Critical patent/JP2007517037A/ja
Publication of JP2007517037A5 publication Critical patent/JP2007517037A5/ja
Pending legal-status Critical Current

Links

JP2006547316A 2003-12-30 2004-12-21 RARγレチノイド受容体の選択的アゴニストとしての二置換カルコンオキシム Pending JP2007517037A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53373303P 2003-12-30 2003-12-30
PCT/US2004/043148 WO2005066116A1 (en) 2003-12-30 2004-12-21 Disubstituted chalcone oximes as selective agonists of rarϝ retinoid receptors

Publications (2)

Publication Number Publication Date
JP2007517037A JP2007517037A (ja) 2007-06-28
JP2007517037A5 true JP2007517037A5 (enExample) 2008-02-14

Family

ID=34748950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006547316A Pending JP2007517037A (ja) 2003-12-30 2004-12-21 RARγレチノイド受容体の選択的アゴニストとしての二置換カルコンオキシム

Country Status (6)

Country Link
US (1) US7476673B2 (enExample)
EP (1) EP1704139A1 (enExample)
JP (1) JP2007517037A (enExample)
CA (1) CA2552090A1 (enExample)
MX (1) MXPA06007560A (enExample)
WO (1) WO2005066116A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2881137B1 (fr) * 2005-01-27 2007-03-02 Servier Lab Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SG179453A1 (en) * 2007-03-09 2012-04-27 Sanofi Aventis Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof
CA2751820A1 (en) * 2009-02-10 2010-08-19 Nippon Soda Co., Ltd. Nitrogen-containing compounds and harmful organism control agents
CN101941919B (zh) * 2009-07-07 2014-07-02 天津药物研究院 一种制备顺式肟及肟醚衍生物的方法
GB0915523D0 (en) 2009-09-07 2009-10-07 Genome Res Ltd Cells and methods for obtaining them
AR078171A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas
MX2012006776A (es) 2009-12-14 2012-10-05 Merck Patent Gmbh Inhibidores de la esfingosina quinasa.
AU2010341229A1 (en) 2009-12-17 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
US11026932B2 (en) 2015-09-10 2021-06-08 National University Corporation Okayama University Medicinal composition for preventing or treating inflammatory respiratory disease
PL3380086T3 (pl) 2015-11-25 2022-02-21 Io Therapeutics, Inc. Oporne na cyp26 agonisty selektywne względem rar-alfa w leczeniu nowotworu
CN109952298B (zh) 2017-07-06 2021-09-03 江苏恒瑞医药股份有限公司 吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用
EP3651757A4 (en) * 2017-07-13 2021-08-25 IO Therapeutics, Inc. RECEPTOR SUB-TYPE AND SELECTIVE RETINOID AND REXINOID COMPOUNDS FOR A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTI-CANCER IMMUNOTHERAPY
AU2018326617B2 (en) 2017-08-31 2022-12-01 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
BR112020004611A2 (pt) 2017-09-12 2020-09-24 Jiangsu Hengrui Medicine Co., Ltd. derivado de indol formamida substituído por átomo de deutério, método de preparação do mesmo e aplicações médicas do mesmo
AU2018341099B2 (en) 2017-09-28 2023-11-02 Kenvue Brands Llc Cosmetic compositions and method of treating the skin
AU2020307631B9 (en) * 2019-06-27 2024-07-04 Hangzhou Healzen Therapeutics Co., Ltd. Casein kinase 1ε inhibitor, pharmaceutical composition and application thereof
IL313052A (en) * 2021-11-23 2024-07-01 Io Therapeutics Inc Methods of using rarγ agonists for cancer treatment

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679171B2 (en) 1991-12-18 1997-06-26 Baylor College Of Medicine Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
WO1996011210A1 (en) * 1994-10-07 1996-04-18 Fujisawa Pharmaceutical Co., Ltd. Cyclic hexapeptides having antibiotic activity
US5599967A (en) * 1994-12-29 1997-02-04 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity
US6008204A (en) * 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5723666A (en) * 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5760276A (en) * 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
US6037488A (en) * 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US6048873A (en) * 1998-10-01 2000-04-11 Allergan Sales, Inc. Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
US6313168B1 (en) * 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US6403810B2 (en) * 2000-07-10 2002-06-11 Hoffmann-La Roche Inc. Thiophene derivatives
US6303785B1 (en) * 2000-08-29 2001-10-16 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
JP4118675B2 (ja) 2000-10-02 2008-07-16 エフ.ホフマン−ラ ロシュ アーゲー 気腫治療用新規レチノイド
US20030003517A1 (en) 2001-03-22 2003-01-02 Klein Elliott S. Methods of detecting dissociated nuclear hormone receptor ligands
US20020193403A1 (en) * 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
DE602004019685D1 (de) * 2003-12-26 2009-04-09 Allergan Inc DISUBSTITUIERTE CHALCOGENOXIME MIT ANTAGONISTISCHER WIRKUNG AM RAR(Gamma)-RETINOIDREZEPTOR

Similar Documents

Publication Publication Date Title
JP2007517037A5 (enExample)
JP2010530372A5 (enExample)
JP2018135343A5 (enExample)
JP2005539088A5 (enExample)
EP0931786A3 (en) Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
JP2002508352A5 (ja) 4(3)置換−4(3)−アミノメチル−(チオ)ピラン又はピペリジン誘導体(=ガバペンチン類似体)
JP2010523476A5 (enExample)
JP2010540593A5 (enExample)
JP2005523922A5 (enExample)
JP2004516314A5 (enExample)
JP2007508359A5 (enExample)
JP2004530641A5 (enExample)
JP2002526516A5 (enExample)
JP2009529540A5 (enExample)
JP2004534774A5 (enExample)
JP2010530881A5 (enExample)
JP2007514773A5 (enExample)
JP2010540555A5 (enExample)
JP2008526999A5 (enExample)
JP2010090149A5 (enExample)
JP2013514980A5 (enExample)
JP2009537540A5 (enExample)
JP2008536833A5 (enExample)
JP2010155827A5 (enExample)
JP2004502732A5 (enExample)